Phase 3
Completed N=80
Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
Hyperlipidemia · Blood Pressure · oxidative stress
Source: ClinicalTrials.gov NCT01267227 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
May 2013
Primary outcomePrimary: LDL — 19.67; 20.04; 5.33; 0 mg/dL
Summary
Pterostilbene is one of several stilbenes found in certain berries, particularly blueberries, that have demonstrated pre-clinical benefit to cholesterol, blood pressure, and oxidative stress. The purpose of this study is to evaluate whether pterostilbene will help control cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia meeting inclusion criteria. The investigators also want to look at the safety of pterostilbene in these patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY LDL |
19.67; 20.04; 5.33; 0 | — |
| SECONDARY Blood Pressure |
7.77; 3.67; 6.72; 0 | — |
| SECONDARY Subjective Adverse Effects |
5; 3; 2; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients ≥18 years of age with a previous TC ≥200 mg/dL and/or a LDL ≥100 mg/dL on either no therapy or stable therapy
- Any concomitant cholesterol medication (not listed in the exclusion criteria) must be at a stable dose for at least 2 months prior to baseline laboratory
Exclusion Criteria
- Patients with significant hepatic, renal or gastrointestinal tract disease
- Receiving thiazolidinediones or fibric acid derivatives
- Current overt cardiovascular disease
- Women of reproductive potential not receiving birth control
- Pregnant/nursing women
Data sourced from ClinicalTrials.gov (NCT01267227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.